Leqvio (Inclisiran) Switching Protocols: How to Transition From or To Other LDL-Lowering Drugs

How Inclisiran Works: The Mechanism That Makes Switching Different

Inclisiran works differently from every other cholesterol drug on the market. Understanding that difference is the first step in any rational switching decision.

Statins, ezetimibe, bempedoic acid, and PCSK9 monoclonal antibodies (mAbs) such as evolocumab (Repatha) and alirocumab (Praluent) all act outside the hepatocyte nucleus. Inclisiran acts inside it. Delivered via subcutaneous injection, the drug is taken up by hepatocytes through GalNAc (N-acetylgalactosamine) ligand-receptor binding and then loaded into the RNA-induced silencing complex (RISC). Once inside RISC, inclisiran's antisense strand directs the complex to cleave PCSK9 messenger RNA before it can be translated into protein. [1]

PCSK9 mAbs vs. Inclisiran: same target, different layer

PCSK9 monoclonal antibodies intercept already-secreted PCSK9 protein in the bloodstream. Inclisiran stops the protein from being made in the first place. Both approaches increase LDL-receptor recycling on hepatocyte surfaces, which clears more circulating LDL-C.

The practical consequence: the LDL benefit of a PCSK9 mAb disappears fairly quickly when the drug is stopped (half-life of evolocumab is approximately 11-17 days; alirocumab is approximately 17-20 days) [2]. Inclisiran's LDL effect fades more slowly because the silencing complex remains active inside the hepatocyte for weeks to months after a single dose. [1]

Why the intracellular mechanism changes the switching calculus

Because inclisiran acts upstream of protein secretion, combining it with a PCSK9 mAb offers very limited additional LDL reduction. Blocking a protein that is barely being produced produces minimal incremental benefit. Clinicians should choose one PCSK9-targeting strategy, not both simultaneously. The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol states that PCSK9 inhibitors should be added to maximally tolerated statin therapy when LDL-C remains above goal; it does not recommend combining two PCSK9-targeting mechanisms. [3]

Statin and ezetimibe combinations remain appropriate

Statins upregulate PCSK9 expression as a compensatory response, which is one reason PCSK9 inhibition produces proportionally greater LDL lowering on top of statin therapy than as monotherapy. Inclisiran's ORION-9 trial (heterozygous FH, N=482) showed 39.7% placebo-adjusted LDL-C reduction when added to background statin therapy [4]. Ezetimibe acts at the intestinal cholesterol transporter NPC1L1, a separate mechanism with no interaction with the RISC complex. Continuing statin and/or ezetimibe while starting inclisiran is appropriate and common practice.

The ORION Trial Data: What 50% LDL Reduction Actually Means

The phrase "about 50% LDL reduction" circulates widely. The actual numbers deserve specificity.

ORION-10 (N=1,561, primary prevention-enriched US population with ASCVD) and ORION-11 (N=1,617, global ASCVD/high-risk population) were the key Phase 3 trials published in the New England Journal of Medicine in 2020. [5] Both trials enrolled adults on maximally tolerated statin therapy with LDL-C of 70 mg/dL or higher (ASCVD) or 100 mg/dL or higher (high cardiovascular risk without ASCVD).

Primary endpoints and LDL reductions

In ORION-10, inclisiran produced a time-averaged LDL-C reduction of 51% vs. Placebo (P<0.001). In ORION-11, the time-averaged reduction was 49.9% (P<0.001). [5] Absolute LDL-C values fell from a baseline of approximately 105 mg/dL to approximately 50-55 mg/dL at Day 510 in both trials, sustained across the twice-yearly dosing interval without the mid-cycle LDL rebound seen with biweekly or monthly mAbs.

The "time-averaged" metric matters clinically

PCSK9 mAbs, dosed every 2 or 4 weeks, produce peak LDL lowering around Day 7-14 after each injection, then partial rebound before the next dose. Inclisiran's LDL reduction is relatively flat between doses, meaning the time-averaged exposure to lower LDL is greater per calendar year for an equivalent nadir reduction. A 2021 analysis in the Journal of the American College of Cardiology modeled that inclisiran's flat LDL profile could reduce cardiovascular event risk by a margin that bimonthly dosing schedules do not fully capture due to the inter-dose LDL fluctuation. [6]

Safety signals from ORION-10 and ORION-11

Injection-site reactions occurred in 2.6% of inclisiran-treated patients vs. 0.9% placebo in the pooled analysis, almost all mild and transient. [5] There were no clinically meaningful elevations in liver enzymes, creatine kinase, or new-onset diabetes signals, a profile that distinguishes inclisiran from high-intensity statins in statin-intolerant patients.

Switching From a PCSK9 Monoclonal Antibody to Inclisiran

This is the most clinically common switch request, often driven by patient preference for less frequent dosing, insurance formulary changes, or adherence concerns.

Timing the transition

No pharmacological washout of the PCSK9 mAb is required before starting inclisiran. The mAb's LDL-lowering effect will naturally decline over 3-6 weeks as circulating drug clears. The practical approach:

1. Administer inclisiran's first dose (Day 1, 284 mg subcutaneous) at or shortly after what would have been the patient's next scheduled mAb dose.
2. Give the second inclisiran dose (Day 90, 3 months later).
3. Continue every 6 months thereafter.

By timing the inclisiran start to coincide with the next mAb dose date, there is virtually no gap in LDL coverage. The patient transitions from mAb-maintained LDL suppression to inclisiran-maintained suppression without a meaningful rebound window.

What to tell the patient

LDL-C measured within the first 4-6 weeks after the last mAb dose and before the inclisiran effect is fully established may appear modestly higher than the treated nadir. Reassure the patient this transient rise is expected. A confirmatory LDL-C check at Day 90 (just before the second inclisiran dose) will reflect inclisiran's steady-state effect.

Special case: switching because of injection-site reactions to mAb

Inclisiran injection-site reactions tend to be milder and briefer than those reported with some mAb formulations. The ORION-10/11 rate of 2.6% vs. The 1-3% reported across evolocumab and alirocumab trials is broadly comparable. [5][2] A patient switching specifically for tolerability reasons should be counseled that injection-site reactions with inclisiran are possible, though the frequency is low and the injections occur only twice per year.

Switching From Inclisiran to a PCSK9 Monoclonal Antibody

Situations that drive this switch include: loss of insurance coverage for inclisiran, access to self-injection preferred over office-based administration, pregnancy planning (data on inclisiran in pregnancy is absent; PCSK9 mAb data is minimal but slightly more established), or a patient relocating away from the supervising prescriber.

The 6-month dosing interval creates a natural switching window

Because inclisiran's LDL effect persists for approximately 6 months per dose, a patient who misses their next inclisiran injection will see LDL-C begin to rise within 4-8 weeks as the RISC-loaded silencing complex degrades. The appropriate switch protocol:

1. Start the PCSK9 mAb at the point the patient's next inclisiran dose would have been due, or up to 4 weeks earlier if LDL-C monitoring shows rising values.
2. The overlap risk is minimal because inclisiran's residual intracellular activity and the new mAb's extracellular blockade target the same downstream outcome (LDL-receptor availability) via sequential steps. No safety signal from brief overlap has been documented in published literature, though formal overlap studies are limited.

Monitoring during the transition

Check LDL-C at 4 weeks and 12 weeks after starting the mAb. If LDL-C is not at goal by Week 12, reassess statin dose and ezetimibe use before escalating the mAb dose.

Switching From Statins to Inclisiran (Add-On vs. Replacement)

Inclisiran is not a statin replacement. The FDA indication specifies use "as an adjunct to diet and maximally tolerated statin therapy." [7] A patient being considered for inclisiran should already be on the highest tolerated statin dose, typically rosuvastatin 20-40 mg or atorvastatin 40-80 mg, per ACC/AHA guidelines. [3]

When statin intolerance changes the picture

Patients with verified statin intolerance (confirmed by rechallenge with at least two different statins at the lowest available dose, per the 2022 ACC Expert Consensus) may use inclisiran on a background of non-statin therapy such as ezetimibe 10 mg daily and/or bempedoic acid 180 mg daily. [8] In this scenario, the LDL reduction from inclisiran averages approximately 38-44% vs. The ~50% seen on concurrent statin therapy, because the statin-induced upregulation of PCSK9 is absent.

No statin washout is needed

Statins can be continued or adjusted on the same day inclisiran is started. There is no pharmacokinetic interaction between statins and inclisiran. Inclisiran is not metabolized by CYP enzymes; it is taken up by hepatocytes via the ASGR1 (asialoglycoprotein receptor 1) pathway and does not affect hepatic drug metabolism. [1]

Switching From Ezetimibe or Bempedoic Acid to Inclisiran

Ezetimibe 10 mg daily reduces LDL-C by approximately 18-20% as monotherapy. Bempedoic acid 180 mg daily reduces LDL-C by approximately 17-21% in statin-intolerant patients (CLEAR Outcomes trial, N=13,970). [9] Neither drug competes mechanistically with inclisiran.

The standard clinical approach is to continue both agents and add inclisiran rather than substitute it. However, if a prescriber and patient agree to simplify the regimen after inclisiran achieves goal LDL-C, ezetimibe can be tapered or stopped with repeat LDL-C testing at 6-8 weeks to confirm that target levels are maintained.

A practical decision framework for inclisiran add-on vs. Replacement

Use the following three-question sequence at the point of prescribing:

1. Is the patient on maximally tolerated statin? If no, optimize statin first. Inclisiran on a submaximal statin underperforms its trial results.
2. Is LDL-C still above the patient's risk-stratified goal despite statin plus ezetimibe? If yes, inclisiran is the appropriate next step per ACC/AHA 2022. [3]
3. Is the patient switching from a PCSK9 mAb or adding inclisiran de novo? If switching, time the first inclisiran dose to the patient's next scheduled mAb injection date to avoid an LDL gap.

Inclisiran's Dosing Schedule and Why It Matters for Switching Timing

The dosing schedule is: 284 mg subcutaneous on Day 1, again on Day 90 (plus or minus 2 weeks), then every 6 months (plus or minus 2 weeks) thereafter. [7] This loading-then-maintenance schedule is not arbitrary.

Why two loading doses?

The first dose initiates RISC loading in hepatocytes. LDL-C begins to fall within 2 weeks and reaches nadir by approximately Day 60. The second dose at Day 90 "top-loads" the silencing complex, producing a more sustained and slightly deeper suppression than the first dose alone. After the Day 90 dose, PCSK9 mRNA suppression is sufficient to maintain adequate LDL-receptor upregulation for the full 6-month interval without redosing.

Missed dose flexibility

The label allows a window of plus or minus 3 months for missed maintenance doses. [7] If a patient misses a maintenance dose by more than 3 months, the two-dose loading schedule (Day 1 and Day 90) should be restarted. This restart instruction has direct relevance to the inclisiran-to-mAb switch: if the patient decides to return to inclisiran after a gap on a mAb, the prescriber should treat it as a new loading sequence, not a simple resumption.

Office Administration Requirement: A Practical Switching Barrier

In the United States, inclisiran must be administered by a healthcare provider. It cannot be dispensed to patients for self-injection. [7] This is a meaningful difference from evolocumab and alirocumab, which patients administer at home with autoinjectors. For some patients, the twice-yearly office visit is a convenience advantage; for others, scheduling difficulty is a real barrier.

Switching to inclisiran for adherence reasons makes sense for patients who miss home injections. Switching away from inclisiran to a home-injectable mAb makes sense for patients in rural areas, those with infrequent access to their prescribing clinic, or those who prefer autonomy over the injection process. The ACC/AHA 2022 guideline explicitly identifies patient preference and access as appropriate considerations in PCSK9 inhibitor selection. [3]

Renal and Hepatic Considerations When Switching

Inclisiran is not renally cleared to a meaningful extent. The ORION-1 pharmacokinetic substudy showed no dose adjustment is needed for patients with eGFR as low as 15 mL/min/1.73m2, including those on hemodialysis. [1] This is a notable advantage over drugs with renal clearance, because ASCVD patients often have comorbid chronic kidney disease.

Moderate to severe hepatic impairment (Child-Pugh B or C) has not been studied adequately. Use caution and consider avoiding inclisiran in patients with significant liver dysfunction, where PCSK9 mAbs may be a safer choice given their established data in this population.

Pregnancy and Contraception Considerations

Inclisiran data in pregnancy is absent. The drug's mechanism of intracellular mRNA silencing raises theoretical concerns about fetal exposure, and the GalNAc delivery system targets highly expressed asialoglycoprotein receptors that are also present in placental tissue. Patients of reproductive potential should use effective contraception during treatment. [7]

If a patient becomes pregnant or plans to conceive while on inclisiran, switching to dietary management, bile acid sequestrants, or a PCSK9 mAb with more limited (though still inadequate) pregnancy data may be appropriate after a risk-benefit discussion with the treating physician and an obstetrician.

Drug Interactions: What Not to Worry About

Inclisiran has no known clinically significant drug-drug interactions based on available pharmacokinetic data. [1][7] It does not inhibit or induce CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. It is not a substrate or inhibitor of P-glycoprotein or major drug transporters. Patients on warfarin, immunosuppressants, or polypharmacy regimens can receive inclisiran without dose adjustment of their other medications, which simplifies transitions from complex multi-drug lipid regimens.

Cardiovascular Outcomes: ORION-4 and What We Are Waiting For

The ORION-10 and ORION-11 trials demonstrated LDL-C reduction endpoints; they were not powered for cardiovascular outcomes (MACE). [5] The ongoing ORION-4 trial (N=15,000, UK Biobank-linked population) is a randomized, double-blind trial comparing inclisiran vs. Placebo on top of standard care, with a primary endpoint of MACE. Results are expected around 2026. [10]

Until those data are available, the cardiovascular benefit of inclisiran is inferred from LDL-C reduction and the well-established LDL hypothesis (Mendelian randomization studies and statin/PCSK9 mAb outcome trials collectively support that each 1 mmol/L reduction in LDL-C reduces major vascular events by approximately 22%, per the Cholesterol Treatment Trialists' Collaboration meta-analysis). [11]

The FOURIER trial (evolocumab, N=27,564) demonstrated 15% relative risk reduction in MACE with a 59% LDL-C reduction [12], and the ODYSSEY OUTCOMES trial (alirocumab, N=18,924) demonstrated 15% relative risk reduction with a 54% LDL-C reduction. [13] These outcomes data for PCSK9 mAbs provide the strongest indirect evidence that inclisiran's similar magnitude of LDL reduction will translate to cardiovascular benefit, but prescribers should note that ORION-4 remains the definitive answer.